Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: A message not well taken

Digestive Diseases and Sciences

Volumn 53, Issue 9, 2008, Pages 2359-2365

  Samonakis, Dimitrios N ^a,b   Notas, George ^a,b   Christodoulakis, Nikolaos ^a,b   Kouroumalis, Elias A ^a,b  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

HCC; Lanreotide; Nonsurgical; Octreotide; Somatostatin receptors

Indexed keywords

OCTREOTIDE; PLACEBO; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MECHANISM; HORMONE INHIBITION; HUMAN; LIVER CELL CARCINOMA; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS; OCTREOTIDE; PEPTIDES, CYCLIC; SOMATOSTATIN;

EID: 50249135365     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-0175-9     Document Type: Review

References (56)

1. MB Thomas AX Zhu 2005 Hepatocellular carcinoma: the need for progress J Clin Oncol 23 2892 2899
2. JM Llovet A Burroughs J Bruix 2003 Hepatocellular carcinoma Lancet 362 1907 1917
3. FX Bosch J Ribes M Diaz R Cleries 2004 Primary liver cancer: worldwide incidence and trends Gastroenterology 127 S5 S16
4. G Fattovich T Stroffolini I Zagni F Donato 2004 Hepatocellular carcinoma in cirrhosis: incidence and risk factors Gastroenterology 127 S35 S50
5. M Branda J Wands 2006 Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma Hepatology 43 891 902
6. P Kaposi-Novak J Lee L Gomez-Quiroz C Coulouarn V Factor S Thorgeirsson 2006 Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype J Clin Invest 116 1582 1595
7. S Thorgeirsson J Grisham 2002 Molecular pathogenesis of human hepatocellular carcinoma Nat Genet 31 339 46
8. JM Llovet M Beaugrand 2003 Hepatocellular carcinoma: present status and future prospects J Hepatol 38 Suppl 1 S136 S149
9. M Varela M Sala JM Llovet J Bruix 2003 Review article: natural history and prognostic prediction of patients with hepatocellular carcinoma Aliment Pharmacol Ther 17 Suppl 2 98 102
10. M Mela A Mancuso AK Burroughs 2003 Review article: hepatocellular carcinoma: indications for liver transplantation Aliment Pharmacol Ther 17 Suppl 2 130 137
11. M Schwartz 2004 Liver transplantation in patients with hepatocellular carcinoma Liver Transpl 10 S81 S85
12. TJ Song EW Ip Y Fong 2004 Hepatocellular carcinoma: current surgical management Gastroenterology 127 S248 S260
13. A Burroughs D Hochhauser T Meyer 2004 Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum Lancet Oncol 5 409 418
14. JD Schwartz A Beutler 2004 Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials-II: systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma Anti-Cancer Drugs 15 439 52
15. E Kouroumalis P Skordilis K Thermos A Vasilaki J Moschandrea ON Manousos 1998 Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study Gut 42 442 447
16. DN Samonakis J Moschandreas T Arnaoutis P Skordilis C Leontidis I Vafiades E Kouroumalis 2002 Treatment of hepatocellular carcinoma with long acting somatostatin analogues Oncol Rep 9 903 907
17. D Dimitroulopoulos D Xinopoulos K Tsamakidis A Zisimopoulos E Andriotis D Panagiotakos A Fotopoulou C Chrysohoou A Bazinis D Daskalopoulou E Paraskevas 2007 Lond-acting Octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors. A randomized placebo controlled trial World J Gastroenterol 13 23 3164 3170
18. MF Yuen RT Poon CL Lai ST Fan CM Lo KW Wong WM Wong BC Wong 2002 A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma Hepatology 36 687 691
19. G Becker HP Allgaier M Olschewski A Zahringer HE Blum 2007 Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study Hepatology 45 9 15
20. JM Llovet J Bustamante A Castells R Vilana MC Ayuso M Sala C Bru J Rodes J Bruix 1999 Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials Hepatology 29 62 67
21. DN Samonakis N Christodoulakis EA Kouroumalis 2006 Octreotide for unresectable hepatocellular carcinoma: beyond the first sight J Clin Gastroenterol 40 86 87
22. M Raderer MH Hejna A Kurtaran GV Kornek JB Valencak G Oberhuber F Vorbeck I Virgolini W Scheithauer 1999 Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog Lanreotide Am J Gastroenterol 94 278 279
23. M Raderer MH Hejna C Muller GV Kornek A Kurtaran I Virgolini W Fiebieger G Hamilton W Scheithauer 2000 Treatment of hepatocellular cancer with the long acting somatostatin analog Lanreotide in vitro and in vivo Int J Oncol 16 1197 201
24. D Dimitroulopoulos D Xinopoulos K Tsamakidis A Zisimopoulos E Andriotis S Markidou D Panagiotakos C Chrysohoou A Bazinis E Paraskevas 2002 The role of sandostatin LAR in treating patients with advanced hepatocellular cancer Hepatogastroenterology 49 1245 1250
25. JT Siveke C Herberhold C Folwaczny 2003 Complete regression of advanced HCC with long acting octreotide Gut 52 1531
26. ML Gill M Atiq S Sattar N Khokhar 2005 Treatment outcomes with long acting octreotide in inoperable hepatocellular carcinoma: a local experience and review of literature J Pak Med Assoc 55 135 138
27. JC Reubi 2003 Peptide receptors as molecular targets for cancer diagnosis and therapy Endocr Rev 24 389 427
28. RR Plentz HL Tillmann S Kubicka JS Bleck M Gebel MP Manns KL Rudolph 2005 Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage J Gastroenterol Hepatol 20 1422 1428
29. M Blaker M Schmitz A Gocht S Burghardt M Schulz DC Broring A Pace H Greten A De Weerth 2004 Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas J Hepatol 41 112 118
30. JC Reubi A Zimmermann S Jonas B Waser P Neuhaus U Laderach B Wiedenmann 1999 Regulatory peptide receptors in human hepatocellular carcinomas Gut 45 766 774
31. YC Patel 1999 Somatostatin and its receptor family Front Neuroendocrinol 20 157 198
32. G Ferjoux C Bousquet P Cordelier N Benali F Lopez P Rochaix L Buscail C Susini 2000 Signal transduction of somatostatin receptors negatively controlling cell proliferation J Physiol Paris 94 205 210
33. LJ Hofland PM van Koetsveld N Wouters M Waaijers JC Reubi SW Lamberts 1992 Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells Endocrinology 131 571 577
34. AV Schally 1988 Oncological applications of somatostatin analogues Cancer Res 48 6977 6985
35. G Notas G Kolios N Mastrodimou M Kampa A Vasilaki C Xidakis E Castanas K Thermos E Kouroumalis 2004 Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors J Hepatol 40 792 798
36. SW Lamberts JC Reubi EP Krenning 1994 The role of somatostatin analogs in the control of tumor growth Semin Oncol 21 61 64
37. SW Lamberts AJ van der Lely WW de Herder LJ Hofland 1996 Octreotide N Engl J Med 334 246 54
38. SW Lamberts WW de Herder LJ Hofland 2002 Somatostatin analogs in the diagnosis and treatment of cancer Trends Endocrinol Metab 13 451 457
39. C Bousquet J Guillermet F Vernejoul H Lahlou L Buscail C Susini 2004 Somatostatin receptors and regulation of cell proliferation Dig Liver Dis 36 Suppl 1 S2 S7
40. P Dasgupta 2004 Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis Pharmacol Ther 102 61 85
41. H Huynh P Chow L Ooi K Soo 2002 A possible role for Insulin-like Growth Factor-Binding Protein-3 autocrine/paracrine loops in controlling hepatocellular carcinoma cell proliferation Cell Growth Differ 13 115 122
42. RL Adams IP Adams SW Lindow W Zhong SL Atkin 2005 Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium Br J Cancer 92 1493 1498
43. HL Liu L Huo L Wang 2004 Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells Acta Pharmacol Sin 25 1380 1386
44. M Lasfer N Vadrot AV Schally A Nagy G Halmos D Pessayre G Feldmann FJ Reyl-Desmars 2005 Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238 J Hepatol 42 230 237
45. C Xidakis G Kolios V Valatas G Notas I Mouzas E Kouroumalis 2004 Effect of octreotide on apoptosis-related proteins in rat Kupffer cells: a possible anti-tumour mechanism Anticancer Res 24 833 841
46. H Reynaert K Rombouts A Vandermonde D Urbain U Kumar P Bioulac-Sage M Pinzani J Rosenbaum A Geerts 2004 Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma Gut 53 1180 1198
47. G Notas C Xidakis V Valatas A Vasilaki N Mastrodimou P Manousou G Kolios K Thermos EA Kouroumalis 2005 LPS modifies the expression and accumulation of Somatostatin receptors in rat Kupffer cells J Hepatol 42 Suppl 2 232
48. G Olias C Viollet H Kusserow J Epelbaum W Meyerhof 2004 Regulation and function of somatostatin receptors J Neurochem 89 1057 1091
49. LJ Hofland SW Lamberts 2003 The pathophysiological consequences of somatostatin receptor internalization and resistance Endocr Rev 24 28 47
50. S Corbetta EMG Ballare A Lania M Losa A Di Blasio AM Spada 2001 Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression Eur J Clin Invest 31 208 214
51. V Valatas G Kolios P Manousou G Notas C Xidakis I Diamantis E Kouroumalis 2004 Octreotide regulates CC but not CXC LPS-induced chemokine secretion in rat Kupffer cells Br J Pharmacol 141 477 487
52. V Valatas G Kolios P Manousou C Xidakis G Notas D Ljumovic EA Kouroumalis 2004 Secretion of inflammatory mediators by isolated rat Kupffer cells: the effect of octreotide Regul Pept 120 215 225
53. WA Slijkhuis L Stadheim ZM Hassoun UC Nzeako WK Kremers JA Talwalkar GJ Gores 2005 Octreotide therapy for advanced hepatocellular carcinoma J Clin Gastroenterol 39 333 338
54. G Notas M Kampa AP Nifli K Xidakis D Papasava K Thermos E Kouroumalis E Castanas 2007 The inhibitory effect of opioids on HepG2 cells is mediated via interaction with somatostatin receptors Eur J Pharmacol 555 1 7
55. E Kouroumalis D Samonakis P Skordilis 2003 Octreotide treatment of hepatocellular carcinoma Hepatology 37 477
56. D Deming A Stella K Holen 2005 A dramatic response to long-acting octreotide in metastatic hepatocellular carcinoma Clin Adv Hematol Oncol 3 468 474